This report originally appeared in the August 2009 issue of DOTmed Business News
The medical supply industry is poised to benefit from a substantial increase in the resale market as a trickledown portion of the multibillions in increased traffic from the American Recovery and Reinvestment Act of 2009 (ARRA), which is set to fund $20 billion plus into the Health IT (HIT) space. The legislation also puts $20 billion towards reaching the goal of 90% of doctors engaged in certified Electronic Medical Records (EMR) technology in 10 years-challenging in a strained economy when it can cost $50,000 for one practice to convert to electronic records, but promising for the sales market and consequentially, for the resale market. The implications of all this funding could be a trickle down effect into the medical supply resale market.
Regardless of ARRA impact, the resale market is expected to continue to show modest growth. The U.S. output of medical equipment and supplies expanded by more than 3% in 2008, according to data from the Federal Reserve Board. In 2009, growth for medical products is expected to be about the same, around 3%. The tendency for medical products to post positive growth year after year, even during a recession in the overall economy, has given the medical industry a reputation of being "non-cyclical." The reasoning is that most medical procedures and therapies are essential rather than discretionary; in times of economic duress, Americans might choose to forego a new car or refrigerator, but they will continue to sustain their levels of spending on health care, which requires continuous upgrades and updates of medical products.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
The winners of the ARRA funding will most likely be the usual suspects, big vendors. Large medical technology leaders who participate in high performance products and commodities such as Abbott, Baxter, BD, Medtronic, J&J, GE Healthcare, Siemens, etc., are very much in the hunt for the funding and quite honestly, are likely to receive the majority. However, this can spell good news to value-added resellers (VARs) and used equipment resellers who might be able to take advantage of the consequences. So, if the large vendors are likely to receive the bulk of the grants, and their tendency is to market new equipment, how will the resale market be affected?
Answering this question requires a brief review of the channels required to bring medical products to market. First, at the top of the chain, are the large medical technology leaders who participate in high performance products and commodities, as mentioned previously, who are the ones most likely to receive the bulk of the grant funds. Next, the large supply chain specialists' distributors such as Owens & Minor, Cardinal Health and McKesson, dominate the high volume commodity products. After that, there are hundreds of midsized specialized device manufacturers who sell their products directly through agents, distributors and major gatekeepers. Next are the Healthcare Retailers and Pharmacies; then the multi-level marketing organizations such as Shaklee, Nuskin, etc., and finally, a new, rapidly growing direct-to-consumer television channel and on-line services pioneered by Polymedica and others.